Molecular Evaluation of Pancreatic Cancer

Not Applicable

Recruiting

• Conditions: nresectable or metastatic pancreatic ductal adenocarcinoma or recurrent disease; Unresectable or metastatic pancreatic ductal adenocarcinoma or recurrent disease; Cancer - Pancreatic

• Registration Number: ACTRN12620000762954
• Lead Sponsor: Dr Daniel Croagh

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-07-27
• Last Update Posted: 3 August 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

1. Adults, age 18 years or over, male or female
2. Locally advanced (unresectable) or metastatic biopsy-proven pancreatic ductal adenocarcinoma (PDAC) based on the NCCN guidelines version 2, 2017 criteria or recurrent disease
3. Tumour tissue available for DNA/RNA extraction
4. ECOG Performance Status 0-2
5. Suitability for chemotherapy
6. Provision of informed consent for participation in the study
7. Life expectancy of at least 3 months from the time of screening as judged by screening investigator.

Exclusion Criteria

1. Operable or borderline resectable pancreatic cancer
2. Neuroendocrine pancreatic cancers
3. Evidence of systemic disease (cardiovascular, respiratory, renal, hepatic, etc.) that would preclude chemotherapy.
4. Serious medical or psychiatric conditions that might compromise protocol-based management as judged by investigator

Study & Design

• Study Type: Observational
• Study Design: Not specified